Lv41
680 积分 2025-06-05 加入
Preclinical pharmacokinetics and metabolism of MAK683, a clinical stage selective oral embryonic ectoderm development (EED) inhibitor for cancer treatment
13天前
已完结
Recent update on the development of EZH2 inhibitors and degraders for cancer therapy
30天前
已完结
MK-0457, an Aurora kinase and BCR–ABL inhibitor, is active in patients with BCR–ABL T315I leukemia
4个月前
已完结
Free energy perturbation in the design of EED ligands as inhibitors of polycomb repressive complex 2 (PRC2) methyltransferase
7个月前
已完结
Recent Progress in DNA Damage Response-Targeting PROTAC Degraders
8个月前
已完结
Design and Application of Cereblon-Recruiting Prodegraders
8个月前
已完结
皖公网安备34019202002308
